244
Participants
Start Date
April 23, 2021
Primary Completion Date
October 26, 2022
Study Completion Date
October 26, 2022
IDegLira
"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
Budounoki Clinic, Saga-shi, Saga
Oita Endocrinology Diabetes Clinic, Oita-shi, Oita
Seino Internal Medicine Clinic, Koriyama-shi
Naka Kinen Clinic, Naka
Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi
Jinnouchi Hospital, Kumamoto
Heiwadai Hospital, Miyazaki
Abe Diabetes Clinic_Internal Medicine, Ōita
TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology, Aichi
Kumanomae Nishimura Internal Medical Clinic, Arakawa-ku, Tokyo
Yoshida Hospital, Asahikawa-shi, Hokkaido
Nippon Medical School Hospital, Diabetes,Metabology,Endocrin, Bunkyo-ku, Tokyo
Gengendo Kimitsu Hospital, Chiba
The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo
Soyokaze CardioVascular Medicine and Diabetes Care, Ehime
Kawada Clinic, Gunma
H.E.C Science Clinic, Kanagawa
Chigasaki Municipal Hospital, Kanagawa
Hotaruno hakuyukai Medical Corporation of Japan, Kisarazu-shi, Chiba
Gendai Clinic, Kitakyusyu-shi, Fukuoka
Ohisama Clinic, Kochi-shi, Kochi
Kawasaki Medical School Hospital, Diabetes, Endo and Metabo, Kurashiki-shi, Okayama
The Jikei Medical University Hospital, Minatoku
Takagi hospital, Internal Medicine, Okawa-shi, Fukuoka
Nakajima Diabetes Clinic, Osaka
Matsuda Gastroenterology and Diabetes Clinic, Osaka
Okamoto Clinic for Diabetes and Endocrinology, Ōita
Japanese Red Cross Shizuoka Hospital, Shizuoka
Suruga Clinic, Shizuoka-shi, Shizuoka
Oyama East Clinic, Tochigi
Lead Sponsor
Novo Nordisk A/S
INDUSTRY